Vistagen Therapeutics, Inc. (VTGN) Dividend History

Company News

• All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy

  VistaGen Therapeutics (VTGN) has received a rating upgrade to a Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimates, which is a powerful force impacting stock prices. The upgrade positions the company in the top 20% of Zacks-covered stocks in terms of estimate revisions, suggesting the stock might move higher in the near term.

  Benzinga
• Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?

  The mean of analysts' price targets for VistaGen Therapeutics, Inc. (VTGN) points to a 160% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  Zacks Investment Research
• VistaGen Therapeutics (VTGN Stock) Exploded 3,471% Here’s Why

  Are you looking for penny stocks to buy? Are you grappling with… The post VistaGen Therapeutics (VTGN Stock) Exploded 3,471% Here’s Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks
• VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

  SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a company developing therapeutics to transform the treatment paradigm for patients suffering from anxiety, depression and other central nervous system (CNS) disorders, today reported results for its third fiscal quarter ended December 31, 2021 and provided a corporate update.

  GlobeNewswire Inc.
• VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates

  Investing.com

  Featured Companies: AAPL